Antibody Formation

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
BACKGROUND: Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor …
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 …